GNRH1 and benign prostatic hyperplasia: Suppression of sex steroid production on the basis of desensitization and down regulation of pituitary gonadotropin releasing hormone (GnRH) receptor by agonistic GnRH analogues[14] (nafarelin acetate, leuprolide) resulting in the blockage of gonadotropin release from the anterior pituitary gland is a well-established approach in the treatment of BPH.[15, 16] Furthermore, antiandrogens like cyproterone acetate[17] and flutamide[18] competitively inhibit the ligand (DHT) binding to the androgen receptor and are used therapeutically in BPH.